Guideline Recommendations for Muscle‑Relaxant Therapy in Chronic Low‑Back Pain

Efficacy Evidence

The American College of Physicians and American Pain Society state that tizanidine has been well studied for low‑back pain, whereas there is little evidence supporting the efficacy of baclofen or dantrolene for this indication. 1, 2, 3, 4

The American College of Physicians/American Pain Society notes that tizanidine is associated with lower rates of injury, delirium, encephalopathy, falls, and opioid‑overdose compared with baclofen in older adults with musculoskeletal pain. 5

According to the ACP/APS guidelines, both tizanidine and chlorzoxazone can cause reversible, generally non‑serious hepatotoxicity, whereas dantrolene carries a black‑box warning for potentially fatal hepatotoxicity. 5, 1
The Journal of the American Geriatrics Society recommends periodic monitoring of liver‑function tests while patients are receiving either tizanidine or baclofen. 6

First‑line pharmacologic therapy for chronic mechanical back pain should be acetaminophen or NSAIDs (when not contraindicated). 5, 4
If pain persists after first‑line agents, adding tizanidine for short‑term relief is recommended. 1, 2
Duration of muscle‑relaxant therapy should be time‑limited; extended courses are reserved only for patients who continue to benefit without major adverse events. 1, 7

Tizanidine: initiate at 2 mg up to three times daily, then titrate slowly based on clinical response and tolerability. 6, 7
Monitoring for tizanidine should include assessment for muscle weakness, urinary retention, cognitive changes, sedation, and orthostatic hypotension. 6
Baclofen (when tizanidine is contraindicated): start at 5 mg up to three times daily; older adults rarely tolerate doses >30–40 mg per day. 6
Monitoring for baclofen should similarly cover muscle weakness, urinary function, cognitive effects, and sedation. 6
Both agents require avoidance of abrupt discontinuation to prevent CNS irritability (baclofen) or rebound hypertension/tachycardia (tizanidine). 6

Cardiovascular monitoring: both tizanidine and baclofen can cause hypotension and bradycardia; tizanidine has a particular risk of orthostatic hypotension, so blood pressure and heart rate should be checked during titration. 5
Renal impairment: tizanidine clearance is markedly reduced when creatinine clearance < 25 mL/min, making dose reduction safer than using baclofen, which carries a high risk of encephalopathy in chronic kidney disease. 5

All facts are derived from guideline statements or peer‑reviewed evidence with the cited references indicated.

Tizanidine is supported by eight randomized trials demonstrating efficacy for acute low‑back pain, whereas baclofen and dantrolene each have only two trials for this indication, indicating a substantially stronger evidence base for tizanidine. [8][9]

Only one low‑quality trial of cyclobenzaprine has evaluated a muscle‑relaxant for chronic low‑back pain, and that study did not report pain‑intensity or global‑efficacy outcomes, leaving the effectiveness of cyclobenzaprine in this setting uncertain. [8][9]
The majority of muscle‑relaxant trials in low‑back pain were short‑duration (≤ 2 weeks); only a single 3‑week trial exists, so long‑term efficacy data for chronic low‑back pain are essentially absent. [8][9]

For acute low‑back pain, muscle‑relaxants provide moderate superiority to placebo for short‑term pain relief, with a reported risk ratio (RR) of 0.80 at 2–4 days; however, this benefit cannot be extrapolated to chronic use. [8][9]

All muscle‑relaxants are associated with a higher total adverse‑event rate compared with placebo (RR = 1.50) and a higher central‑nervous‑system adverse‑event rate (RR = 2.04), although serious complications remain rare. [8][9]
Diazepam (a benzodiazepine) shows no difference from cyclobenzaprine for short‑term global improvement, but it produces more frequent CNS adverse events (e.g., somnolence, fatigue, light‑headedness) than placebo. 8

Current trials provide insufficient evidence to determine the overall effect of skeletal muscle relaxants on chronic low‑back pain. Three small, methodologically limited trials yielded inconsistent results, preventing a definitive conclusion about efficacy. Evidence level: low‑quality. 10
Tetrazepam (a benzodiazepine) demonstrated a reduced likelihood of no pain improvement at 5–7 days and 10–14 days compared with placebo. This finding is based on two high‑quality randomized trials in patients with chronic low‑back pain. Evidence level: high‑quality. 10

Use of muscle relaxants is associated with a higher risk of central‑nervous‑system adverse events, primarily sedation, compared with placebo. The pooled risk ratio is 2.04. Evidence level: moderate. 10
Overall adverse‑event rates are increased with muscle relaxants versus placebo (risk ratio 1.50), although serious complications remain rare. Evidence level: moderate. 10
Carisoprodol should be avoided because it is metabolized to meprobamate, a scheduled substance with abuse potential. Recommendation: strong. 11
Dantrolene is contraindicated for chronic low‑back pain due to a black‑box warning for potentially fatal hepatotoxicity. Recommendation: strong. 11